Hepatitis B Virus (HBV) Consensus Statement

The Hepatitis B Virus (HBV) Consensus Statement highlights important aspects of HBV management in Australia. This clinical resource was developed by a collaborative effort of specialists in hepatology, infectious diseases, general practice and nursing. Additional expertise was provided by a consumer oversight group of people with lived-experience and representatives from communities most affected by HBV. 
A list of contributors is included in the document. Members of the Steering Committee that guided the resource development are also listed on the GESA Committees page. 

This new resource replaces the GESA DHF 2nd edition from 2009/10 titled  “Australia and New Zealand Chronic Hepatitis B (CHB) Recommendations”.

The 2021 Hepatitis B Virus (HBV) Consensus Statement comprises 32 recommendations covering six important areas of HBV management:

  • Prevalence, transmission and priority populations,
  • Natural history,
  • Diagnosis and monitoring,
  • Antiviral treatment,
  • Complications and
  • Special groups (those with pregnancy, viral co-infection and renal impairment).

 

A summary of the recommendations has been published by the Medical Journal of Australia.

The HBV Consensus Statement was also provided for review and endorsement by the following organisations that contributed to the development of the resource:

  • The Australian Chinese Medical Association of Victoria (ACMAV)

  • The Australian College of Remote and Rural Medicine (ACRRM) 

  • The Australasian Hepatology Association (AHA) 

  • The Australian Indigenous Doctors’ Association (AIDA) 

  • The Australian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM)

  • The Australasian Society for Infectious Diseases  (ASID)

  • The Royal Australasian College of Physicians (RACP) 

  • Hepatitis Australia 

  • The Liver Foundation